Viridian Therapeutics Inc
NASDAQ:VRDN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.6
25.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Viridian Therapeutics Inc
Viridian Therapeutics Inc
Net Income (Common)
Viridian Therapeutics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Viridian Therapeutics Inc
NASDAQ:VRDN
|
Net Income (Common)
-$257.1m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-46%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$126m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-35%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$4.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
-$479.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
1%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4.7B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
30%
|
|
Viridian Therapeutics Inc
Glance View
In the bustling frontier of biotechnology, Viridian Therapeutics Inc. emerges as a dynamic player, carving a niche within the field of precision medicine. Founded with the mission to revolutionize treatment regimens for serious diseases, Viridian channels its expertise into developing innovative therapies for rare and underserved conditions. The company primarily focuses on advancing its pipeline of monoclonal antibodies to combat and manage thyroid eye disease (TED), a rare autoimmune disorder. By leveraging cutting-edge research and development, Viridian harnesses its scientific prowess to translate complex biological insights into promising therapeutic candidates. The meticulous process involves extensive clinical trials and regulatory navigation, ensuring that only robustly tested solutions reach the medical community. Viridian's business model hinges on strategic collaborations, licensing agreements, and scientific innovation. It navigates the intricate landscape of biotechnology by forging alliances with research institutions and industry leaders to bolster its R&D capabilities. These collaborations not only expedite the drug development process but also provide opportunities for licensing and milestone payments, supplementing early-stage revenue. Ultimately, the true engine of Viridian’s financial performance lies in successfully bringing its therapeutic offerings to the market. In this competitive sphere, generating revenue manifests through the commercialization of their approved treatments, and as these therapies gain traction in medical circles, the company anticipates a revenue stream through product sales and partnerships, cementing its position as a leader in targeted therapies for rare conditions.
See Also
What is Viridian Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-257.1m
USD
Based on the financial report for Sep 30, 2024, Viridian Therapeutics Inc's Net Income (Common) amounts to -257.1m USD.
What is Viridian Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-46%
Over the last year, the Net Income (Common) growth was -19%. The average annual Net Income (Common) growth rates for Viridian Therapeutics Inc have been -22% over the past three years , -44% over the past five years , and -46% over the past ten years .
You don't have any saved screeners yet
